Plasma C-Peptide Concentration and Risk of Hypoglycemia in People with T2DM treated with Insulin Glagine 300 U/mL (Gla-300) or Insulin Glargine 100 U/mL (Gla-100)

Abstract

Risk of hypoglycaemia on insulin treatment increases as B-cell function progressively deteriorates in Type 2 diabetes. Using data from the EDITION 1, 2 and 3 treat-to-target trials in T2DM, we analyzed baseline fasting plasma C-peptide concentration and hypoglycemia during 6 months treatment with Gla-300 vs Gla-100 to explore if C-peptide was associated with hypoglycemia risk. C-peptide levels <0.4 nmol/L were more frequent in previously insulin-treated participants in EDITION 1and 2 trials (54%) compared with the insulin-naïve in EDITION 3 (12.5%). Comparable numbers of participants treated with Gla-300 or Gla-100 had lower C-peptide (EDITION 1, 221 vs 209; EDITION 2, 207 vs 216; EDITION 3, 52 vs 43).